Xenikos is developing a novel therapy that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos’ mission is to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

LATEST NEWS

27 juni 2022

Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

8 september 2021

Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor

19 juli 2021

Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

TO ALL NEWS

Introducing T-Guard®

T-Guard® is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, acute graft-versus-host disease (aGVHD), solid-organ rejection and several severe autoimmune diseases.

A Patient’s Story

Jan Willem was diagnosed with a rare form of leukemia in 1994. His diagnosis was the start of a remarkable journey to recovery that demonstrates the potential of T-Guard® as a life-saving treatment option.

OUR INVESTORS